DSM and Phynova reach global distribution agreement for blood glucose-support ingredient
Phynova has signed a global distribution and collaboration agreement for its Reducose ingredient with DSM.
Photo © stock.adobe,com/6okean
Phynova (Oxfordshire, UK) has signed a global distribution and collaboration agreement for its Reducose ingredient with DSM (Kaiseraugst, Switzerland). Reducose is a patented water extract of white mulberry leaves (Morus alba) that supports healthy blood glucose levels by reducing the absorption of sugars and other carbohydrate by up to 40%, says the company.
“We are delighted to work with DSM, the leading global health and nutrition ingredient specialist,” said Robert Miller, CEO of Phynova, in a press release. “Along with the distribution and sales of Reducose, we will collaborate closely with them on product development, clinical research, regulatory approvals, and marketing.”
“Phynova is a strategic partner for DSM to provide the right nutritional solutions to address the ever-growing health concerns linked to maintaining healthy blood glucose,” explained Ivo Lansbergen, VP global strategic marketing, DSM Human Nutrition and Health, in a press release. “The combined strengths of DSM and Phynova provide an excellent platform for addressing this major societal challenge.”
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
